110 results about "Renal Cell Cancers" patented technology

The invention discloses an HLA-A * 11: 01 renal cell carcinoma tumor antigen short peptide derived from an IDO1 gene. The invention provides a tumor antigen peptide. The amino acid sequence of the tumor antigen peptide is as shown in SEQ ID No. 1. Researches find that a compound formed by the oligopeptide and a corresponding HLA molecule (HLA-A * 11: 01) can be recognized by T cells, and immune response is activated. The invention provides a potential target spot for treatment of renal cell carcinoma, and provides a new target spot screening direction for subsequent tumor antigen treatment of renal carcinoma.

The present disclosure relates to detecting one or more types of urinary system cancer in a biological sample from a subject. In particular, the present disclosure provides compositions and methods for detecting the presence or absence of one or more types of urinary system cancer (e.g., urothelial carcinoma and / or renal cell carcinoma) in a biological sample from a subject suffering from or suspected of suffering from urinary system cancer.

The invention discloses a medicine for treating renal cell carcinoma and application thereof, and belongs to the field of biomedicine, the medicine comprises a reagent capable of ubiquitination degradation of WEE1, FBXO2 overexpression can prevent proliferation and movement of renal cell carcinoma cells, and FBXO2 can reduce abundance of WEE1 through ubiquitination degradation; the interaction and ubiquitination degradation of the WEE1 are mediated by the FBA structural domain of the FBXO2; fBXO2 degrades WEE1 through ubiquitination to inhibit RCC canceration.

The invention discloses an HLA (Human Leukocyte Antigen)-A * 11: 01 renal cell carcinoma tumor antigen short peptide derived from long-chain non-coding RNA (Ribonucleic Acid) LINC02717. The invention provides a tumor antigen peptide. The amino acid sequence of the tumor antigen peptide is as shown in SEQ ID No. 1. Researches find that a compound formed by the oligopeptide and a corresponding HLA molecule (HLA-A * 11: 01) can be recognized by T cells, and immune response is activated. The invention provides a potential target spot for treatment of renal cell carcinoma, and provides a new target spot screening direction for subsequent tumor antigen treatment of renal carcinoma.

The invention belongs to the technical field of image classification, and particularly relates to a renal cell carcinoma sinus invasion prediction method based on prior information, and the method comprises the steps: obtaining a CT image, and constructing a renal cell carcinoma sinus invasion prediction data set according to the CT image; performing feature extraction on the data in the data set, and constructing a heterogeneous graph according to an extracted feature graph; inputting the heterogeneous graph into the trained priori-driven graph neural network model to obtain a renal cell carcinoma sinus invasion prediction result; evaluating the prediction result; according to the method, different potential appearances are generated in a data driving mode through a diffusion perturbation strategy, and disturbance invariant features are learned, so that reduction correction is carried out on network performance degradation caused by cross-dataset application.

The invention provides a molecular target for preparing a medicine for treating TFE3 gene rearrangement renal cell carcinoma and application of the molecular target, and relates to the technical field of biological medicine. The molecular target is an LGI3 gene, and the base sequence of the LGI3 gene is as shown in SEQ ID No. 1. After the LGI3 is interfered, the proliferation, migration and invasion capabilities of the TFE3 rearrangement renal cell carcinoma can be effectively inhibited, so that the LGI3 gene is expected to be used as a molecular target to be applied to clinical treatment of patients with the TFE3 rearrangement renal cell carcinoma.

This disclosure is directed to two cancer-associated fibroblast (CAP) subtypes, namely permissive (permCAF) and restraining (restCAF), in pancreatic ductal adenocarcinoma (PDAC), mesothelioma, urothelial carcinoma, or renal cell carcinoma. Methods are disclosed that describe how to identify a tumor sample as a perCAF or a restCAF subtypes. Methods are also disclosed that use the subtypes for diagnosis, prognosis, differential treatment, and treatment.

The invention relates to the technical field of biotechnology or biomedical engineering, in particular to hydrogel, bio-ink, organoids constructed by using the hydrogel, a drug screening model and a construction method. The hydrogel is prepared from 3 to 4 weight percent of gelatin, 0.5 to 2 weight percent of sodium alginate, 20 to 40 weight percent of matrigel and a cell culture medium. The hydrogel is helpful for improving the bionic degree of a tumor microenvironment, can be used for preparing bio-ink containing target cells such as tumor cells, particularly can be used for preparing bio-ink of primary cells (such as primary renal cell carcinoma cells), and an organ-like model constructed by using the bio-ink under a proper 3D biological printing condition is uniform in growth and high in biocompatibility. The cell growth speed is high, the consistency with parent tissues is high, the in-vitro amplification time of the patient-derived tumor cells can be shortened, the influence of subculture factors on the cell affinity can be reduced, the drug development progress can be accelerated, and the production cost can be reduced.

The invention belongs to application of PLOD2 as a biomarker in preparation of a product for detecting sarcoma-like renal cell carcinoma, and belongs to the field of biomedicine. The invention finds that PLOD2 is a molecular marker of sarcoma-like renal cell carcinoma, the expression of PLOD2 in sarcoma-like renal cell carcinoma is significantly higher than that in non-sarcoma-like renal cell carcinoma and normal kidney tissue, and in the same sarcoma-like renal cell carcinoma tissue, the expression of PLOD2 in a sarcoma-like component is significantly higher than that in an adjacent epithelioid renal cell carcinoma component and paracancerous normal kidney tissue. Therefore, PLOD2 can be used as an auxiliary diagnosis molecular marker of sarcoma-like renal cell carcinoma, and has important clinical application value for improving the clinical diagnosis level of the disease.

Provided is an antibody fusion protein, which simultaneously targets CD24, IL4R and an integrin receptor. An in-vitro assay shows that the antibody fusion protein significantly inhibits the proliferation, migration, invasion, colony formation and adhesion of renal cancer cells, also has a comprehensive and significant anti-tumor effect on gastric cancer, colon cancer and breast cancer, and has the effect of inhibiting angiogenesis. The results of a mouse tumor model of subcutaneous transplantation of MC38-hPDL1C57BL6 / J show that the antibody fusion protein combined with the PDL1 antagonist atezolizumab can significantly inhibit tumor growth. The antibody fusion protein can be used as a potential candidate drug for treating metastatic renal cell carcinoma, PDL1-overexpressing cancer, ophthalmic diseases and inflammation or autoimmune diseases.

The present invention provides a method for preparing and using a CD70-specific diagnostic-integrated molecular imaging probe, which comprises a tumor targeting group and a radionuclide, the tumor targeting group being selected from a CD70-specific nanobody or a CD70-specific nanobody fusion protein, the CD70-specific nanobody being B3 or B6 having the amino acid sequences set forth in SEQ ID NO. 1 and SEQ ID NO. 3, and the CD70-specific nanobody fusion protein being ABDB3 or ABDB6 having the amino acid sequences set forth in SEQ ID NO. 5 and SEQ ID NO. 7. The present invention achieves noninvasive visualization of human CD70 molecule expression and realizes noninvasive diagnosis of renal cell carcinoma. This probe has the advantages of simple preparation, low cost, high specificity, high stability, short imaging cycle, low radiation dose, and easy clinical translation.

The application discloses an HLA-A*11:01 renal cell carcinoma tumor antigen short peptide derived from a long-chain non-coding RNA SLC12A5-AS1 and application thereof. The application provides a tumor antigen peptide, and an amino acid sequence of the tumor antigen peptide is shown as SEQ ID No. 1. It is found by the application that a complex formed by the short peptide and a corresponding HLA molecule (HLA-A*11:01) can be recognized by T cells, and an immune response is activated. The application provides a potential target for renal cell carcinoma treatment, and provides a new target screening direction for subsequent tumor antigen treatment of renal cell carcinoma.

The application discloses application of a reagent for detecting AHSP protein in preparation of a product for diagnosing prostate cancer, and relates to the technical field of biological medicine; through proteomic analysis, ELISA test on urine protein of prostate cancer patients, clear cell renal cell carcinoma patients and normal healthy men, and immunohistochemical analysis on file wax blocks of the prostate cancer patients, normal prostate tissues around the cancer, prostate tissues of prostatic hyperplasia and clear cell renal cell carcinoma tissues, it is found that the AHSP protein has a certain relationship with the occurrence and development of prostate cancer, and can be used for assisting diagnosis of the prostate cancer; and in urine detection, AHSP has higher sensitivity than PSA, and when PSA is negative or serum PSA is low, AHSP can form complementation with ASHP, thereby helping to improve the diagnosis rate and non-invasive screening ability; through research on the relationship between the AHSP protein and the prostate cancer, the diagnosis rate of patients can be improved, non-invasive reexamination after treatment is facilitated, drug use is guided, and the survival rate is improved.

The invention discloses application of CBX7 in prognosis prediction and treatment of renal cell carcinoma. The reagent for detecting the expression level of CBX7 is applied to preparation of auxiliary diagnosis or auxiliary prediction products for metastasis and prognosis of renal cell carcinoma. The relationship between expression of CBX7 in renal cell carcinoma tissues and patient metastasis and prognosis is researched for the first time, and it is found that the overall lifetime and progression-free lifetime of CBX7 low-expression renal cell carcinoma patients are short. Therefore, the CBX7 can be used as a marker for predicting metastasis and prognosis of the renal cell carcinoma, can assist in prognosis evaluation of patients with the renal cell carcinoma by detecting the expression level of the CBX7 in renal cell carcinoma tissues, and also has important guiding significance for postoperative monitoring and treatment of the patients with the renal cell carcinoma.

The invention relates to the technical field of diagnosis, in particular to a prognosis evaluation kit and evaluation method for renal cell carcinoma patients based on DNAJA1 protein expression quantity. The method for evaluating the prognosis and immune microenvironment state of the RCC patient based on the DNAJA1 expression level provided by the invention has good stability, accuracy and operability, can realize hierarchical management and individualized treatment guidance of patient risks, and has remarkable clinical and social values.

The present invention relates to a biomarker for diagnosing renal cell carcinoma and a use thereof. The biomarker specifically increases or decreases in expression in renal cell carcinoma patients compared to a normal group and can thus be used for monitoring, diagnosing, and predicting the prognosis of renal cell carcinoma. In particular, the biomarker can be effectively used for the early diagnosis of renal cell carcinoma.

The application discloses a kind of kidney cell cancer patient prognosis risk prediction methods based on multi-modal deep learning.The present application processes whole field digital pathology section (WSI) image and pathological diagnosis report by deep learning algorithm, extracts text features using natural language processing model, extracts image features using computer vision model and ABMIL network, and carries out multi-modal feature fusion through Cross-attention Transformer network, and finally outputs the survival risk curve of patient changes with time in combination with Weibull survival function, for assisting doctor to carry out more accurate prognosis evaluation and survival analysis.

A system, computer readable medium, apparatus and / or method for non-invasive, non-surgical, digital biopsy. The system, computer readable medium, apparatus and / or method accurately predicts benign kidney lesions from cancers in a patient. A processor may receive patient clinical factors, texture analysis of computer-tomographic imaging, and an artificial intelligence learning model. By implementing artificial intelligence, the processor may then predict or determine a probability of kidney cancer in the patient using the patient clinical factors, the texture analysis of computer-tomographic imaging, and the artificial intelligence learning model. Notably, the prediction is performed without needing invasive biopsy surgery and subsequent pathology analysis to arrive at a diagnosis but relies on radiomics metrics.

The presently disclosed subject matter provides cells, compositions, and methods for enhancing immune responses to tumor antigens. These cells comprise a first antigen-recognizing receptor that targets CD70. These cells have improved activity and / or efficiency. The present invention also provides a method for reducing tumor burden in a subject with renal cell carcinoma, pancreatic cancer, or ovarian cancer, comprising administering to the subject an effective amount of cells comprising a TCR-like fusion molecule that targets CD70.

The invention discloses an HLA-A * 11: 01 renal cell carcinoma tumor antigen short peptide derived from long-chain non-coding RNA SLC12A5-AS1 and application of the HLA-A * 11: 01 renal cell carcinoma tumor antigen short peptide. The invention provides a tumor antigen peptide. The amino acid sequence of the tumor antigen peptide is as shown in SEQ ID No. 1. Researches find that a compound formed by the oligopeptide and a corresponding HLA molecule (HLA-A * 11: 01) can be recognized by T cells, and immune response is activated. The invention provides a potential target spot for treatment of renal cell carcinoma, and provides a new target spot screening direction for subsequent tumor antigen treatment of renal carcinoma.

The invention relates to a novel cyclopeptide medicine PT-C10 with anti-tumor activity. The amino acid sequence of the novel cyclopeptide medicine PT-C10 is shown as SEQ ID NO: 1. The cyclic peptide has a good killing effect on renal cell carcinoma cells and is suitable for treating renal cell carcinoma. The invention also provides a preparation method of the cyclopeptide through microwave-promoted Fmoc protection solid-phase synthesis, and an application of the cyclopeptide in preparation of antitumor drugs. Experimental results show that the IC50 of the cyclopeptide PT-C10 to the 786-O kidney cancer cells is 42.23 mu M, and the IC50 of the cyclopeptide PT-C10 to the A498 kidney cancer cells is 15.53 mu M, so that the cyclopeptide PT-C07 can obviously reduce the cell viability of the 786-O and the A498 and shows obvious killing efficacy. The cyclic peptide PT-C10 provides a new treatment strategy for patients with renal cell carcinoma, and is expected to improve the treatment effect and the life quality of the patients.

Disclosed herein are novel compounds that are Mpsl / TTK inhibitors. Also disclosed are compositions comprising the compounds and methods of using the compounds in treating various diseases. In some embodiments, some such compounds, compositions, and their uses may be useful for the treatment of cancer. In some implementations, the cancer is brain cancer, glioblastoma multiforme, head and neck cancers, colorectal cancer, stomach or gastric cancer, pancreatic cancer, melanoma, bladder cancer, kidney cancer, renal cell carcinoma, breast cancer, ovarian cancer, lymphoma, thyroid cancer, mesothelioma, sarcoma, lung cancer, non-small cell lung cancer, small cell lung cancer, or endometrial cancer.

The present application provides an application of an RIPK1 O-GlcNAc glycosylation inhibitor in the preparation of a drug for enhancing the sensitivity of sunitinib to renal cell carcinoma. The present application discovers that RIPK1 O-GlcNAc glycosylation, especially the O-GlcNAc glycosylation of serine at positions 331, 440, and 669, reduces the sensitivity of renal cell carcinoma to sunitinib. Therefore, by inhibiting RIPK1 O-GlcNAc glycosylation or knocking down the expression of O-GlcNAc transferase, the sensitivity of renal cell carcinoma to sunitinib can be increased. Therefore, the O-GlcNAc glycosylation level of RIPK1 can be used as a biomarker for predicting the sensitivity of renal cell carcinoma to sunitinib; by using an RIPK1 O-GlcNAc glycosylation inhibitor to reduce the RIPK1 O-GlcNAc glycosylation level, especially the O-GlcNAc glycosylation of serine at positions 331, 440, and 669, the sensitivity of renal cell carcinoma to sunitinib can be increased, and the therapeutic effect of sunitinib can be improved.

The invention relates to a novel cyclopeptide drug PT-C07 with antitumor activity. The amino acid sequence of the novel cyclopeptide drug PT-C07 is shown as SEQ ID NO: 1. The cyclic peptide has a good killing effect on renal cell carcinoma cells and is suitable for treating renal cell carcinoma. The invention also provides a preparation method of the cyclopeptide through microwave-promoted Fmoc protection solid-phase synthesis, and an application of the cyclopeptide in preparation of antitumor drugs. Experimental results show that the IC50 of the cyclopeptide PT-C07 to the 786-O kidney cancer cells is 77.53 mu M, and the IC50 of the cyclopeptide PT-C07 to the A498 kidney cancer cells is 67.06 mu M, so that the cyclopeptide PT-C07 can obviously reduce the cell viability of the 786-O and A498 and shows obvious killing efficacy. The cyclic peptide PT-C07 provides a new treatment strategy for patients with renal cell carcinoma, and is expected to improve the treatment effect and the life quality of the patients.

The present disclosure relates to the detection of one or more types of urological cancer in a biological sample from a subject. In particular, the present disclosure provides compositions and methods for detecting the presence or absence of one or more types of urological cancer (e.g., urothelial carcinoma and / or renal cell carcinoma) in a biological sample from a subject having or suspected of having urological cancer.

This invention belongs to the field of image classification technology, specifically relating to a method for predicting sinus invasion of renal cell carcinoma based on prior information. The method includes: acquiring CT images; constructing a renal cell carcinoma sinus invasion prediction dataset based on the CT images; extracting features from the data in the dataset; constructing a heterogeneous graph based on the extracted feature maps; inputting the heterogeneous graph into a trained prior-driven graph neural network model to obtain the renal cell carcinoma sinus invasion prediction result; and evaluating the prediction result. This invention generates different potential appearances in a data-driven manner through a diffusion perturbation strategy and learns perturbation-invariant features, thereby correcting for the network performance degradation caused by cross-dataset applications.

The presently disclosed subject matter relates to antibodies and antigen-binding fragments that bind specifically to phosphorylated PDGFRA, and methods of treating cancer expressing MAN2A1-FER which ectopically phosphorylates PDGFRA. MAN2A1-FER can be expressed in liver cancer, prostate cancer, brain cancer, glioblastoma multiforme, breast cancer, lung cancer, non-small cell lung cancer, colon cancer, and renal cell carcinoma.

The present technology provides compounds, as well as compositions including such compounds, useful for imaging and / or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and / or a prostate cancer.

The invention belongs to the field of chemical synthesis, and particularly relates to a small molecule compound K-H03 with an anti-tumor effect and application of the small molecule compound K-H03 in anti-tumor drugs, and the small molecule compound has a structural formula as shown in a formula I. The compound has a good killing effect on renal cell carcinoma cells and is suitable for treating renal cell carcinoma. The invention also provides a method for preparing the compound and application of the compound in preparation of antitumor drugs. Experimental results show that the IC50 of the K-H03 to the 786-O kidney cancer cells is 203.0 [mu] M, and the IC50 of the K-H03 to the A498 kidney cancer cells is 175.5 [mu] M, which indicates that the K-H03 can obviously reduce the cell viability of the 786-O and A498 and shows obvious killing efficacy. The K-H03 provides a new treatment strategy for patients with renal cell carcinoma, and is expected to improve the treatment effect and the life quality of the patients.

The present disclosure provides chimeric antigen receptors that bind to Axl and Ror2, and conditionally active chimeric antigen receptors (CARs) that recognize Axl and Ror2. Furthermore, provided herein are nucleic acids encoding these CARs and methods of making and using the CARs, including methods of treating cancer, especially cancers that express Axl and / or Ror2, such as renal cell carcinoma. The present disclosure provides cells genetically modified to produce the CARs.